Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction
Latest Information Update: 17 Feb 2026
At a glance
- Drugs Autologous mesenchymal stem cell therapy Pharmicell (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors Pharmicell
Most Recent Events
- 17 Feb 2026 New trial record